{"id":947,"date":"2024-11-25T14:30:52","date_gmt":"2024-11-25T13:30:52","guid":{"rendered":"https:\/\/jmc-finanz.ch\/?p=947"},"modified":"2026-02-17T12:03:10","modified_gmt":"2026-02-17T11:03:10","slug":"aphaia-pharma-to-participate-in-a-panel-discussion-at-the-1st-annual-obesity-metabolic-innovation-forum","status":"publish","type":"post","link":"https:\/\/jmc-finanz.ch\/en\/aphaia-pharma-to-participate-in-a-panel-discussion-at-the-1st-annual-obesity-metabolic-innovation-forum\/","title":{"rendered":"Aphaia Pharma to Participate in a Panel Discussion at the 1st Annual Obesity &#038; Metabolic Innovation Forum"},"content":{"rendered":"<p>ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, November 25, 2024 \u2013 Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the <a href=\"https:\/\/obesityinnovationforum.com\/events\/obesity-innovation-forum\">1<sup>st<\/sup> Annual \u00a0Obesity &amp; Metabolic Innovation Forum<\/a>, taking place December 4, 2024, in Boston, Massachusetts. The panel will provide unique perspectives on the rapid growth of GLP-1 drugs and their potential to address the root causes of chronic diseases, such as obesity.<\/p>\n<p><strong>Details on the presentation are as follows:<\/strong><\/p>\n<p><strong>Panel:<\/strong> The Future of GLP-1 Drugs \u2013 A Panacea for Chronic Disease?<\/p>\n<p><strong>Date: <\/strong>Wednesday, December 4, 2024, at 3:30 p.m. EST<br \/>\n<strong>Location:<\/strong> Convene One Boston Place<\/p>\n<p><strong>Aphaia Investor Contact<br \/>\n<\/strong>G\u00fcnter Jucho<br \/>\nChief Financial Officer<br \/>\n<a href=\"mailto:jucho@aphaiapharma.com\">jucho@aphaiapharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, November 25, 2024 \u2013 Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-947","post","type-post","status-publish","format-standard","hentry","category-press"],"acf":[],"_links":{"self":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/comments?post=947"}],"version-history":[{"count":3,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/947\/revisions"}],"predecessor-version":[{"id":967,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/posts\/947\/revisions\/967"}],"wp:attachment":[{"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/media?parent=947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/categories?post=947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jmc-finanz.ch\/en\/wp-json\/wp\/v2\/tags?post=947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}